GENZ completes Renagel trial

Genzyme (GENZ) completed its 1-year, open-label Treat-to-Goal trial comparing its Renagel sevelamer with calcium-based phosphate binders in hemodialysis patients. The company will not pursue a 2-year extension protocol, at the recommendation of its clinical investigators and Renagel advisory board, because GENZ felt the trial met its objectives at year 1. The trial is comparing the effects of Renagel and calcium salts on serum phosphorus, calcium, calcium-phosphorus product and intact parathyroid hormone levels. The study protocol called for physicians to bring phosphorous, calcium and parathyroid levels into predetermined "goal" ranges. ...